Results 11 to 20 of about 23,223 (305)
Signal Transduction and Targeted Therapy, 2021 Chimeric antigen receptor-based T-cell immunotherapy is a promising strategy for treatment of hematological malignant tumors; however, its efficacy towards solid cancer remains challenging.
Duan Siliang, Xiaobing Jiang, Wei Shi
exaly +2 more sources
Nanobody Technology: A Versatile Toolkit for Microscopic Imaging, Protein–Protein Interaction Analysis, and Protein Function Exploration [PDF]
Frontiers in Immunology, 2017 Over the last two decades, nanobodies or single-domain antibodies have found their way in research, diagnostics, and therapy. These antigen-binding fragments, derived from Camelid heavy chain only antibodies, possess remarkable characteristics that favor
Els Beghein, Jan Gettemans
doaj +4 more sources
Nanobody-Displaying Flagellar Nanotubes [PDF]
Scientific Reports, 2018 In this work we addressed the problem how to fabricate self-assembling tubular nanostructures displaying target recognition functionalities. Bacterial flagellar filaments, composed of thousands of flagellin subunits, were used as scaffolds to display ...
Jankovics, Hajnalka +6 more
core +6 more sources
Novel nanobody-161 binds tumor necrosis factor receptor 2 (TNFR2) to exert an anti-tumor effect but does not block TNFα-binding [PDF]
Frontiers in ImmunologyBackgroundTumor necrosis factor receptor 2 (TNFR2) is expressed on regulatory T cells (Tregs) and many cancer cells indicating its potential as a therapeutic target.
Liang Huang +20 more
doaj +2 more sources
Structure of Nanobody Nb23 [PDF]
Molecules, 2021 Background: Nanobodies, or VHHs, are derived from heavy chain-only antibodies (hcAbs) found in camelids. They overcome some of the inherent limitations of monoclonal antibodies (mAbs) and derivatives thereof, due to their smaller molecular size and higher stability, and thus present an alternative to mAbs for therapeutic use.
Percipalle M. +4 more
openaire +5 more sources
Development of camelid monoclonal nanobody against SLC39A6 zinc transporter protein [PDF]
Iranian Journal of Basic Medical Sciences, 2021 Objective(s): SLC39A6 (solute carrier family 39) or LIV-1, is a zinc-transporter protein associated with estrogen-positive breast cancer and its metastatic spread.
Hajarsadat Ghaderi +4 more
doaj +1 more source
Seminars in Immunology, 2021 For treatment and diagnosis of cancer, antibodies have proven their value and now serve as a first line of therapy for certain cancers. A unique class of antibody fragments called nanobodies, derived from camelid heavy chain-only antibodies, are gaining increasing acceptance as diagnostic tools and are considered also as building blocks for chimeric ...
Elisha R, Verhaar +2 more
openaire +3 more sources
Screening, Expression, and Identification of Nanobody against SARS-CoV-2 Spike Protein
Cells, 2022 Coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an infectious disease that has become a serious burden on global public health.
Qianling Su +11 more
doaj +1 more source
Antibodies, 2020 Since their first description in 1993 [...]
Patrick Chames, Ulrich Rothbauer
openaire +3 more sources
Journal of Hematology & Oncology, 2023 Background T cell engagers (TCEs) have been established as an emerging modality for hematologic malignancies, but solid tumors remain refractory. However, the upregulation of programmed cell death 1 (PD-1) is correlated with T cell dysfunction that ...
Ziqiang Ding +12 more
doaj +1 more source